Keywords:
Molecular imaging, Pelvis, Oncology, Cone beam CT, MR-Diffusion/Perfusion, PET-CT, Biopsy, Computer Applications-Detection, diagnosis, Metastases, Image verification, Image registration
Authors:
F. Kossov1, T. van Steenbergen2, M. Smits2, N. Mehra2, T. Scheenen2, P. Zamecnik2, V. Panov1, J. J. Futterer2; 1Moscow/RU, 2Nijmegen/NL
DOI:
10.26044/ecr2019/C-0652
Aims and objectives
Advanced prostate cancer (APCa) is highly malignant and impacts the quality of life in patients worldwide [1].
Lymph nodes and bone are the most common sites for metastases of prostate cancer [2].
In most cases APCa becomes androgen independent which significantly deteriorates the prognosis for this patient [3].
Metastatic castration resistant prostate cancer (mCRPC) is a diagnostic challenge to the physician.Unfortunately,
mCRPC is does not respond well to treatment.
Effective screening should therefore be applied to identify and differentiate the lesions,
especially in the bone at an early/localized stage [4].
Recently,
implementation of imaging modalities such as magnetic resonance imaging (MRI),
radio-labeled prostate-specific membrane antigen (PSMA) and ligands positron emission tomography with the combination of computed tomography (PET/CT) significantly improved the detection and differentiation of bone metastases [5][6][7].
The main limitation of most radiological studies is the absence of histological verification of the detected changes.
Knowledge of the histological composition of the lesion in conjunction with radiological findings could be helpful for choosing optimal therapeutic strategies and in developing responding criteria for treatment.
The aim of our study was to investigate the properties of bone metastases (BM) in CRPC patients by molecular imaging (MRI and 68Ga-PSMA PET/CT) with bone biopsy histopathology as the gold standard.
This poster details the first part of the study in which the MRI imaging parameters were evaluated and compared with the biopsy histopathology.
The second step is to try to estimate degree of malignancy of BM by advanced histopathology analysis and correlate the results for molecular imaging.